Neuroendocrine tumors of the pancreas: etio-pathogenesis, diagnosis, current treatment

Kokhanenko, N. Yu.; Моргошия, Т. Ш.

doi:10.16931/1995-5464.20182100-110

Ann. hir. gepatol.

2018

DOI: 10.16931/1995-5464.20182100-110

|View full text |Cite

Neuroendocrine tumors of the pancreas: etio-pathogenesis, diagnosis, current treatment

N. Yu. Kokhanenko¹,

Т. Ш. Моргошия²

Abstract: Review is devoted to current problems of classification, diagnosis and treatment of pancreatic neuroendocrine tumors. According to modern views, all pancreatic neuroendocrine tumors over 5 mm or those followed by clinical manifestations are biologically malignant. It is shown that certain proportion of pancreatic neuroendocrine tumors are non-functioning. Diagnosis of neuroendocrine tumors is highly difficult issue. Currently, surgery is only radical and adequate approach for functioning pancreatic tumors. Nee… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

<sup>68</sup>Ga-DOTATATE PET/CT Capabilities in Diagnosing of Neuroendocrine Tumors Recurrence

Nosov

Popov

Розенгауз

et al. 2022

jour

View full text Add to dashboard Cite

Relevance: Timely detection and assessment of the prevalence of pancreatic neuroendocrine tumors (p-NETs), visualization of the status of somatostatin receptors, along with morphological characteristics, fundamentally affects the tactics of treatment and long-term prognosis. In recent years, a highly specific diagnostic method 68Ga-DOTATATE PET/CT has become available in Russia. Purpose: Evaluation of the effectiveness of 68Ga-DOTATATE PET/CT in staging and detection of p-NETs recurrence in comparison with routine visualization methods. Material and methods: 68Ga-DOTATATE PET/CT was enrolled in 55 patients diagnosed with p-NETs. Information on previous treatment was studied, as well as reports and images of CT and MRI performed no earlier than 2 months before PET/CT. In all patients, we counted foci of pathological accumulation (FPA) of 68Ga-DOTATATE, both the total number and their distribution in various organs and anatomical zones. The number of FPA on PET/CT was compared with the number of metastases on CT and MRI. Verification of FPA was carried out by follow up PET/CTs, as well as histological examination of the surgical material obtained after the resection of tumor foci after PET/CT. Results: Out of 55 patients, FPA were detected in 48 (87.3 %). Metastases were observed on CT and MRI in 36 patients (65.5 %). 68Ga-DOTATATE PET/CT compared with previous CT and MRI helped to identify an additional 12 people with tumor lesions. The localization of the tumor process on PET/CT completely coincided with CT and MRI in 21 patients. In five patients, the malignant process on PET/CT was detected in the same anatomical areas or lymph nodes as on CT and MRI, but additional foci were detected in these areas. In seven patients, PET/CT revealed distant lung, small pelvis and bone metastases, which were not detected earlier. Secondary isolated liver lesions were detected on CT and MRI in 10 patients. PET/CT revealed additional metastases in lymph nodes and bones in three of them. Secondary lymph node lesions on PET/CT was registered in 24 patients. On CT and MRI in 13 (diameter ≥10 mm). According to CT and MRI, metastases were detected only in the abdomen in 34 patients. PET/CT data matched in 20 (58.8 %) of them. In 14 patients (41.2 %): additional foci were found in the liver, lymph nodes, pelvis and bones. Lung metastases were detected on CT and PET/CT only in one case. Bone lesions on PET/CT were noted in eight patients, on CT and MRI in two. In four patients, primary multiple neuroendocrine tumors of other localizations (small, large intestine, kidney) were detected. Another four patients had multiple p-NETs. Conclusion: 68Ga-DOTATATE PET/CT makes a significant contribution to the assessment of the p-NETs prevalence, allows optimizing the tactics of antitumor treatment.

show abstract

<sup>68</sup>Ga-DOTATATE PET/CT Capabilities in Diagnosing of Neuroendocrine Tumors Recurrence

Nosov

Popov

Розенгауз

et al. 2022

jour

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neuroendocrine tumors of the pancreas: etio-pathogenesis, diagnosis, current treatment

Cited by 1 publication

References 29 publications

<sup>68</sup>Ga-DOTATATE PET/CT Capabilities in Diagnosing of Neuroendocrine Tumors Recurrence

<sup>68</sup>Ga-DOTATATE PET/CT Capabilities in Diagnosing of Neuroendocrine Tumors Recurrence

Contact Info

Product

Resources

About